Mycophenolate mofetil for myasthenia gravis: An open-label pilot study

@article{Ciafaloni2001MycophenolateMF,
  title={Mycophenolate mofetil for myasthenia gravis: An open-label pilot study},
  author={Emma Ciafaloni and Janice M. Massey and B Tucker-Lipscomb and Donald B. Sanders},
  journal={Neurology},
  year={2001},
  volume={56},
  pages={97 - 99}
}
In an open-label study, 12 patients with refractory MG or who were taking only corticosteroids and required additional immunosuppression received mycophenolate mofetil 1 g twice daily for 6 months. A reduction of three points in a quantified MG score and two points in a manual muscle test or a reduction of 50% in corticosteroid dose defined efficacy. Eight patients improved, beginning after 2 weeks to 2 months. No major side effects were observed. 
Mycophenolate Mofetil for Myasthenia Gravis A Double‐Blind, Placebo‐Controlled Pilot Study
TLDR
A double‐blind, placebo‐controlled pilot trial of MM in the treatment of suboptimally controlled, stable MG shows promising and suggestive of greater improvement in the patients who received MM compared to placebo. Expand
Mycophenolate mofetil for myasthenia gravis
TLDR
A retrospective analysis of the use of mycophenolate mofetil in 85 patients with autoimmune myasthenia gravis indicates improvement in treatment response, and Quantitative strength testing performed on the majority of patients before and after treatment improved. Expand
Mycophenolate mofetil for myasthenia gravis: a clear and present controversy
TLDR
This article critically reviews the medical literature on MMF’s use in MG and suggests further research avenues on this topic. Expand
Lessons from Two Trials of Mycophenolate Mofetil in Myasthenia Gravis
TLDR
Two randomized controlled trials of mycophenolate mofetil in the treatment of myasthenia gravis demonstrated efficacy in the population of patients studied, but there are valuable lessons in the way these studies were developed and performed. Expand
Mycophenolate mofetil – as an adjunctive immunosuppressive therapy in refractory myasthenia gravis: The Singapore experience
TLDR
MyM is an effective adjunctive therapy for the treatment of severe, refractory and steroid-dependent MG in the experience and no serious adverse effects were observed. Expand
Mycophenolate mofetil in myasthenia gravis: the unanswered question
TLDR
This paper critically reviews the existing evidence on the efficacy of MMF, the best tolerated immunosuppressant in MG, and provides the authors' view of its role in current practice. Expand
Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis
TLDR
Mycophenolate appears to be a useful addition to the armamentarium of immunosuppressants for treatment of chronic immunologically mediated neuromuscular diseases. Expand
Mycophenolate in treatment‐resistant inflammatory neuropathies
TLDR
Five consecutive patients with treatment‐resistant chronic inflammatory demyelinating polyradiculoneuropathy or multifocal motor neuropathy who were treated with mycophenolate showed clinically significant benefit, but did not result in the reduction in the dose of corticosteroid or other immunosuppressive agents in any patient. Expand
Mycophenolate mofetil and myasthenia gravis
TLDR
Mycophenolate mofetil (MMF) has shown promising effects in MG patients in preliminary studies and is currently being studied in two prospective, randomized, double-blind, placebo controlled, multicenter trials to better establish its role in the treatment of MG. Expand
Mycophenolate mofetil and myasthenia gravis
TLDR
Mycophenolate mofetil (MMF) has shown promising effects in MG patients in preliminary studies and is currently being studied in two prospective, randomized, double-blind, placebo controlled, multicenter trials to better establish its role in the treatment of MG. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 15 REFERENCES
PLACEBO-CONTROLLED STUDY OF MYCOPHENOLATE MOFETIL COMBINED WITH CYCLOSPORINE AND CORTICOSTEROIDS FOR PREVENTION OF ACUTE REJECTION
TLDR
MMF significantly reduced the rate of biopsy-proven rejection or other treatment failure during the first 6 months after transplantation and was well tolerated, although the 3 g dose was somewhat less well tolerated. Expand
A review of clinical experience with the novel immunosuppressive drug mycophenolate mofetil in renal transplantation.
TLDR
Mycophenolate mofetil offers an improved immunosuppressive therapy following renal transplantation and its adverse event profile resembles that of triple therapy with azathioprine. Expand
Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil
TLDR
A patient with severe refractory myasthenia gravis (MG) who experienced an excellent response to mycophenolate mofetil is presented who was placed on escalating doses of pyridostigmine without benefit. Expand
Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.
TLDR
This study demonstrated that MMF administered at a dosage of 2 g or 3 g daily, in combination with maintenance CsA and corticosteroids as triple therapy following ATGAM® induction therapy, is more effective than an otherwise identical regimen that includes azathioprine instead of MMF in preventing acute allograft rejection in first cadaveric renal transplant patients. Expand
Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.
TLDR
Mycophenolate mofetil, a new immunosuppressant that selectively inhibits proliferation of T and B lymphocytes, may reduce the frequency and severity of acute graft rejection in adult patients during the first 6 months after renal transplantation. Expand
Myasthenia gravis
TLDR
This report presents the work of the Task Force and proposes classification systems and definitions of response to therapy designed to achieve more uniformity in recording and reporting clinical trials and outcomes research. Expand
Myasthenia gravis activities of daily living profile
TLDR
The MG-ADL is an easy-to-administer survey of MG that correlates well with the QMG and can serve as a secondary efficacy measurement in clinical trials. Expand
Macroprolactinemia in Childhood and Adolescence: A Cause of Asymptomatic Hyperprolactinemia
TLDR
Upon detection of hyperprolactinemia with no clinical manifestations and no alteration of the remaining endocrine functions, macroprolACTinemia should be considered as a possible diagnosis. Expand
Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF).
TLDR
Clinically attainable concentrations of MPA suppress the proliferation of human arterial smooth muscle cells and may decrease the risk of lymphoma development and proliferative arteriopathy in long-term recipients of MMF. Expand
The importance of formal serum iron studies in the assessment of restless legs syndrome
TLDR
A comparatively large number of patients with RLS responded favorably to blood transfusion or therapy with iron, and relatively small patient populations had raised questions about the nature of iron abnormalities in RLS. Expand
...
1
2
...